Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Finasteride Spray (CU-40102) in Androgenetic Alopecia
NCT05135468Phase 3Completed
- Sponsor
- Cutia Therapeutics
- Start
- Dec 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of DA-4001C in androgenetic alopecia (AGA) (2 arms), sponsored by Cutia Therapeutics. Primary endpoint: Target Area Hair Count at 24 weeks. Started Dec 2021; status: completed.
02
Drugs
DA-4001C
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05135468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135468.